Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Ghosh HS, Patel RV, Claus EB, Gonzalez Castro LN, et al. Neuro Oncol 2025;27:993-1003.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ghosh HS, Patel RV, Claus EB, Gonzalez Castro LN, et al. Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Neuro Oncol 2025;27:993-1003.
PMID: 39584448